Umbilical Mesenchymal Stromal Cells as Cellular Immunotherapy for Septic Shock: A Phase II RCT

脐带间充质基质细胞作为感染性休克的细胞免疫疗法：II 期随机对照试验

• 批准号: 466352
• 负责人: McIntyre Lauralyn A
• 金额: $ 96.07万
• 依托单位: Ottawa Hospital Research Institute
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2022
• 资助国家: 加拿大
• 起止时间: 2022-07-01 至 2025-07-01
• 项目状态: 未结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=466352&lang=en
• 关键词: Adults; Biological Outcomes; Clinical Outcomes; Mesenchymal Stromal Cells; Mulit-Organ Dysfunction; Phase Ii; Placebo Controlled; Randomized Controlled Trial; Septic Shock; Umbilical Cord

Severe infection with shock (septic shock) in the intensive care unit (ICU) accounts for approximately 20% of admissions, of which 20 to 40% will die. Septic shock is associated with an uncontrolled inflammatory response that is initiated by an infectious

重症监护室（ICU）中的严重感染伴休克（败血性休克）约占入院人数的20%，其中20%至40%将死亡。感染性休克与感染性休克引起的不受控制的炎症反应有关。